Fractyl Health, Inc. (GUTS) stock
GUTSNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
$1.08+0.11 (+11.87%)
Close on Nov 18, 2026Market cap $171.91MP/E –Yield –
Fractyl Health r&d expenses
Research and development expenses are spending on new products and technology.
Fractyl Health's R&D Expenses for the twelve months ending Jun 30, 2026 was $63.36M, down 20.7% year over year. For fiscal 2025 it was $74.54M, up 5.8% from the year before.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $74.54M | +5.8% |
| FY2024 | Dec 31, 2024 | $70.47M | +85.3% |
| FY2023 | Dec 31, 2023 | $38.04M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $13.81M | -34.7% |
| Q1 FY2026 | Mar 31, 2026 | $15.60M | -19.7% |
| Q4 FY2025 | Dec 31, 2025 | $16.49M | -18.7% |
| Q3 FY2025 | Sep 30, 2025 | $17.46M | -8.1% |
| Q2 FY2025 | Jun 30, 2025 | $21.15M | +26.2% |
| Q1 FY2025 | Mar 31, 2025 | $19.44M | +34.7% |
| Q4 FY2024 | Dec 31, 2024 | $20.28M | +99.5% |
| Q3 FY2024 | Sep 30, 2024 | $19.00M | +102.6% |
| Q2 FY2024 | Jun 30, 2024 | $16.76M | +83.4% |
| Q1 FY2024 | Mar 31, 2024 | $14.42M | +54.3% |
| Q4 FY2023 | Dec 31, 2023 | $10.17M | – |
| Q3 FY2023 | Sep 30, 2023 | $9.38M | – |
| Q2 FY2023 | Jun 30, 2023 | $9.14M | – |
| Q1 FY2023 | Mar 31, 2023 | $9.35M | – |
See a number that looks wrong?